The Search for Causes of Idiopathic Intracranial Hypertension

Ireland, Belinda

doi:10.1001/archneur.1990.00530030091021

Cited by 172 publications

(114 citation statements)

References 63 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…6 A study by Ireland et al undertook a small case-control study of 40 cases and 39 controls that examined potential risk factors for PTCS. 7 The study found a non-statistically significant increase in risk (Odds Ratio = 2.50, 95% CI: 0.95-6.54) among women who took HCs within 12 months of PTCS diagnosis. 7 However, with only 40 cases of PTCS, there was insufficient statistical power to draw any conclusions from this study.…”

Section: Introductionmentioning

confidence: 77%

Risk of Pseudotumor Cerebri Syndrome (PTCS) with hormonal contraceptive use

Sodhi

Sheldon

Carleton

et al. 2018

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Hormonal contraceptives (HC), one of the most prescribed classes of medication in women, have been linked with pseudotumor cerebri syndrome (PTCS). To date, no large epidemiologic study has examined this association.Methods: A case-control study using the IMS LifeLink Pharmetrics Plus database was conducted. Cases had an ICD-9-CM code for benign intracranial hypertension as well as a procedural code for a CT or MRI and a code for lumbar puncture procedure within 15 days of the PTCS code. Controls were selected from the cohort using density-based sampling.Results: From a cohort of 9,053,240 subjects, there were 288 cases of PTCS corresponding to 2,880 controls. The adjusted RRs for two or more prescriptions of oral combined contraceptive was 0.62 (95% confidence interval 0.39-0.99). RRs for overall HC use was 0.91 (95% CI 0.39-2.12) for one prescription of HCs and 0.69 (95% CI 0.45-1.05) for two or more prescriptions. The RRs for one and two or more prescriptions of progestin only HCs were 0.75 (95% CI 0.08-7.46) and 1.06 (95% CI 0.42-2.69), respectively.Conclusions: Overall HC use does not have a significant effect on incidence of PTCS, however harm associated with progestin-only contraceptives cannot be excluded.

show abstract

Section: Introductionmentioning

confidence: 77%

Risk of Pseudotumor Cerebri Syndrome (PTCS) with hormonal contraceptive use

Sodhi

Sheldon

Carleton

et al. 2018

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…Most "etiologic" agents for pediatric pseudotumor cerebri have only been described within case series and anecdotal LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES reports, demonstrating association but not necessarily cause. Given the rarity of these "etiologic" agents, they have not been confirmed in a recent case-control study, 20 presumably because of the necessary sample size. For this reason, we were not selective in attributing cause once Dandy's modified criteria were met.…”

Section: Resultsmentioning

confidence: 98%

Pediatric Pseudotumor Cerebri: Descriptive Epidemiology

Gordon

1997

Can. j. neurol. sci.

122

View full text Add to dashboard Cite

show abstract

“…There is no published evidence substantiating a causal relationship between PTCS and hormonal contraception [Digre and Corbett 2001;Ireland et al 1990]. The patient described in the case report cited by the authors [Martinez et al 2010] did not meet the diagnostic criteria for PTCS.…”

Section: Risk Of Intracranial Hypertension With Intrauterine Levonorgmentioning

confidence: 99%

Risk of intracranial hypertension with intrauterine levonorgestrel

Friedman

2015

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

The Search for Causes of Idiopathic Intracranial Hypertension

Cited by 172 publications

References 63 publications

Risk of Pseudotumor Cerebri Syndrome (PTCS) with hormonal contraceptive use

Risk of Pseudotumor Cerebri Syndrome (PTCS) with hormonal contraceptive use

Pediatric Pseudotumor Cerebri: Descriptive Epidemiology

Risk of intracranial hypertension with intrauterine levonorgestrel

Contact Info

Product

Resources

About